New York, January 10, 2026, 14:04 EST — Market closed
- Nasdaq announced Walmart will take AstraZeneca’s spot in the Nasdaq-100 ahead of the January 20 open. AZN is also exiting multiple Nasdaq-100 variants.
- AstraZeneca’s shares on the U.S. market ended the day at $94.65, marking a 0.68% gain.
- Investors are turning their attention to AstraZeneca’s management talks at the J.P. Morgan Healthcare Conference from Jan. 12-14, followed by the company’s full-year results due on Feb. 10.
AstraZeneca PLC’s U.S.-listed shares will exit the Nasdaq-100 on Jan. 20, with Walmart stepping in as its replacement, Nasdaq announced Friday. Walmart revealed in November plans to shift its listing from the New York Stock Exchange to Nasdaq.
This matters since the Nasdaq-100 is closely followed by index funds and ETFs that trade stocks just to match the benchmark. When a stock falls out, those funds usually have to trim their positions, no matter what’s going on with the company itself.
AstraZeneca faces a calendar-driven trade layered onto its usual drugmaker issues. Some investors shrug off any shifts around the change as mere noise; others attempt to get ahead of the rebalancing.
AstraZeneca’s ADRs ended Friday at $94.65, gaining 0.68%, based on Nasdaq’s historical data. Trading volume hit roughly 6.1 million shares.
The stock remains near its recent peak, trading roughly 2.6% below its 52-week high of $96.51 hit on Jan. 7, according to MarketWatch data.
Index deletions don’t always make a big splash, but they can shake up trading near the effective date. When there is an impact, it’s typically driven by liquidity and timing, not a change in earnings potential.
AstraZeneca, headquartered in Cambridge, England, markets cancer and respiratory drugs and is listed in New York via an American depositary receipt, or ADR — a U.S.-traded certificate representing a stake in foreign shares.
AstraZeneca’s next key event is the J.P. Morgan Healthcare Conference in San Francisco, running Jan. 12-14, per its investor relations page. Full-year and Q4 results come shortly after, on Feb. 10.
Investors are tuning in for shifts in the company’s 2026 outlook — new launches, progress in oncology, and clues about demand stability after a robust start to the year. Currency fluctuations linger in the background for this UK-based firm reporting in dollars.
The Nasdaq-100 drop doesn’t reflect a verdict on AstraZeneca’s pipeline. Flow-driven sell-offs could reverse fast if long-only investors jump back in. The real risk lies in a guidance slip or disappointing trial results—those would outweigh any index-related moves.
Trading will next pivot around the Jan. 20 index change, followed by a second key moment on Feb. 10 when results and outlook are updated.
